Publications
Where expertise meets impact
Berry doesn’t just follow industry standards — we set them. Our team of award-winning statisticians, journal editors, and regulatory advisors leads the field in Bayesian and adaptive trial design. With research published in The New England Journal of Medicine, JAMA, and The Lancet, we’re driving innovation where it matters most.
Over 90% of our scientists published influential work this past year, advancing adaptive, Bayesian, and platform trial methodology. Our blend of academic rigor, regulatory insight, and real-world experience makes Berry a true authority in modern clinical trials.
Explore our most impactful peer-reviewed publications below.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Science Direct
Neuroscience
Rare Diseases
Platform
Bayesian model of disease progression in mucopolysaccaridosis IIIA
August 15, 2022
2022
doi.org/10.1016/j.cct.2022.106822
JAMA Network Open
Infectious Disease
Cohort Study
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge A Cohort Study and Randomized Comparative Effectiveness Trial
July 14, 2022
2022
doi:10.1001/jamanetworkopen.2022.20957
Taylor & Francis
Oncology
Meta-analysis
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design
July 11, 2022
2022
doi.org/10.1080/10428194.2022.2095624
PLOS One
Infectious Disease
COVID-19
Meta-analysis
Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis
July 8, 2022
2022
doi: 10.1371/journal.pone.0270668. eCollection 2022.
Springer Nature
Infectious Disease
Stopping Rules
Prophylaxis in healthcare workers during a pandemic: a model for a multi-centre international randomised controlled trial using Bayesian analyses
June 27, 2022
2022
doi.org/10.1186/s13063-022-06402-w
Orphanet Journal of Rare Diseases
Methodology
Rare Diseases
Bayesian Drug Development
Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles
May 7, 2022
2022
doi: 10.1186/s13023-022-02342-5.
Springer Nature
Methodology
Allocation
Bandit Procedures for Designing Patient-Centric Clinical Trials
April 12, 2022
2022
doi.org/10.1007/978-3-031-01926-5_14
JAMA Network Open
Infectious Disease
COVID-19
Cohort Study
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19
April 12, 2022
2022
doi:10.1001/jamanetworkopen.2022.6920
No results found.
There are no results with this criteria. Try changing your search.